{"id":"https://openalex.org/W4389956942","doi":"https://doi.org/10.1161/circ.148.suppl_1.14720","title":"Abstract 14720: Persistence and Adherence to Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies and Ezetimibe in Real - World Settings","display_name":"Abstract 14720: Persistence and Adherence to Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies and Ezetimibe in Real - World Settings","publication_year":2023,"publication_date":"2023-11-07","ids":{"openalex":"https://openalex.org/W4389956942","doi":"https://doi.org/10.1161/circ.148.suppl_1.14720"},"language":"en","primary_location":{"id":"doi:10.1161/circ.148.suppl_1.14720","doi":"https://doi.org/10.1161/circ.148.suppl_1.14720","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1161/circ.148.suppl_1.14720","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070905671","display_name":"Lama Ghazi","orcid":"https://orcid.org/0000-0002-9930-3575","observed_orcids":["https://orcid.org/0000-0002-9930-3575"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lama Ghazi","raw_affiliation_strings":["Univ of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039528349","display_name":"Jenna Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenna Jones","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056799708","display_name":"Lisandro Dami\u00e1n Colantonio","orcid":"https://orcid.org/0000-0001-8742-1788","observed_orcids":["https://orcid.org/0000-0001-8742-1788"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisandro Colantonio","raw_affiliation_strings":["Univ of Alabama at Birmingham, Birmingham, AL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Alabama at Birmingham, Birmingham, AL, United States","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067539740","display_name":"Bharat Poudel","orcid":"https://orcid.org/0000-0003-2958-2561","observed_orcids":["https://orcid.org/0000-0003-2958-2561"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bharat Poudel","raw_affiliation_strings":["Univ of Alabama at Birmingham, Birmigham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Alabama at Birmingham, Birmigham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101533062","display_name":"Ying Rong Wen","orcid":"https://orcid.org/0000-0003-0867-3958","observed_orcids":["https://orcid.org/0000-0003-0867-3958"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Wen","raw_affiliation_strings":["Univ of Alabama at Birmingham, Birmigham, AL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Alabama at Birmingham, Birmigham, AL, United States","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100641437","display_name":"Zhixin Wang","orcid":"https://orcid.org/0000-0003-2383-1010","observed_orcids":["https://orcid.org/0000-0003-2383-1010"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhixin Wang","raw_affiliation_strings":["Univ of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101686163","display_name":"Ligong Chen","orcid":"https://orcid.org/0000-0002-5095-9485","observed_orcids":["https://orcid.org/0000-0002-5095-9485"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ligong Chen","raw_affiliation_strings":["Univ of Alabama at Birmingham,, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Alabama at Birmingham,, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048484359","display_name":"Vera Bittner","orcid":"https://orcid.org/0000-0001-9456-850X","observed_orcids":["https://orcid.org/0000-0001-9456-850X"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vera A Bittner","raw_affiliation_strings":["Univ Alabama Birmingham, Birmiham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ Alabama Birmingham, Birmiham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037890696","display_name":"Mark Woodward","orcid":"https://orcid.org/0000-0001-9800-5296","observed_orcids":["https://orcid.org/0000-0001-9800-5296"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Woodward","raw_affiliation_strings":["Univ of Oxford, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ of Oxford, Sydney, Australia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000512041","display_name":"Bethany A. Kalich","orcid":"https://orcid.org/0000-0002-1220-3484","observed_orcids":["https://orcid.org/0000-0002-1220-3484"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bethany Kalich","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, United States","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060465607","display_name":"Robert S. Rosenson","orcid":"https://orcid.org/0000-0002-5599-0633","observed_orcids":["https://orcid.org/0000-0002-5599-0633"]},"institutions":[{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert S Rosenson","raw_affiliation_strings":["Mt Sinai Sch Medicine, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mt Sinai Sch Medicine, New York, NY","institution_ids":["https://openalex.org/I98704320"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015273113","display_name":"Nafeesa N Dhalwani","orcid":"https://orcid.org/0000-0003-3204-1328","observed_orcids":["https://orcid.org/0000-0003-3204-1328","https://orcid.org/0000-0001-7368-3306"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nafeesa Dhalwani","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, United States","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"148","issue":"Suppl_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.5029000043869019,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11620","display_name":"Medication Adherence and Compliance","score":0.5029000043869019,"subfield":{"id":"https://openalex.org/subfields/2714","display_name":"Family Practice"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.48579999804496765,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pcsk9-monoclonal-antibodies","display_name":"PCSK9 monoclonal antibodies","score":0.8889999985694885},{"id":"https://openalex.org/keywords/ezetimibe","display_name":"ezetimibe","score":1.0},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.8820000290870667},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.9819999933242798},{"id":"https://openalex.org/keywords/cholesterol-lowering-therapy","display_name":"cholesterol-lowering therapy","score":0.7590000033378601},{"id":"https://openalex.org/keywords/atherosclerotic-cardiovascular-disease","display_name":"atherosclerotic cardiovascular disease","score":0.8999999761581421},{"id":"https://openalex.org/keywords/statin-therapy","display_name":"statin therapy","score":0.8539999723434448},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.7289999723434448},{"id":"https://openalex.org/keywords/medicare-beneficiaries","display_name":"Medicare beneficiaries","score":0.5659999847412109},{"id":"https://openalex.org/keywords/pharmacy-claims-data","display_name":"pharmacy claims data","score":0.5220000147819519},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.38999998569488525},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.4059999883174896},{"id":"https://openalex.org/keywords/ldl-cholesterol-target-attainment","display_name":"LDL cholesterol goal attainment","score":0.33799999952316284}],"concepts":[{"id":"https://openalex.org/C2778657065","wikidata":"https://www.wikidata.org/wiki/Q417997","display_name":"Ezetimibe","level":3,"score":0.9923376441001892},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9312801361083984},{"id":"https://openalex.org/C2776839432","wikidata":"https://www.wikidata.org/wiki/Q954845","display_name":"Statin","level":2,"score":0.7368559837341309},{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.695895791053772},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6238863468170166},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5597396492958069},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4791219234466553},{"id":"https://openalex.org/C2781009140","wikidata":"https://www.wikidata.org/wiki/Q7170389","display_name":"Persistence (discontinuity)","level":2,"score":0.4343612492084503},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.25227344036102295},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.13355407118797302},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.08657988905906677},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.06726980209350586},{"id":"https://openalex.org/C187320778","wikidata":"https://www.wikidata.org/wiki/Q1349130","display_name":"Geotechnical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1161/circ.148.suppl_1.14720","doi":"https://doi.org/10.1161/circ.148.suppl_1.14720","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1161/circ.148.suppl_1.14720","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4396552363","https://openalex.org/W4404571560","https://openalex.org/W4401323091","https://openalex.org/W4403822662","https://openalex.org/W4311748260","https://openalex.org/W4409151802","https://openalex.org/W4390124650","https://openalex.org/W4385751240","https://openalex.org/W4315798177","https://openalex.org/W2762966306"],"abstract_inverted_index":{"Introduction:":[0],"Non-statin":[1],"cholesterol-lowering":[2],"therapies":[3],"(proprotein":[4],"convertase":[5],"subtilisin/kexin":[6],"type":[7],"9":[8],"monoclonal":[9],"antibodies":[10],"[PCSK9mAb]":[11],"and":[12,45,59,110,118,175,199,229,245,260,276],"ezetimibe)":[13],"have":[14],"been":[15],"shown":[16],"to":[17,217,226,249,271,284],"reduce":[18],"atherosclerotic":[19],"cardiovascular":[20],"disease":[21],"(ASCVD)":[22],"events":[23],"in":[24,35,74,146],"randomized":[25],"clinical":[26,76],"trials":[27],"of":[28,52,69,136,141,150,161,169,185,190],"patients":[29,53,137,142,205],"treated":[30],"with":[31,94,106,143,277],"statin":[32],"therapy.":[33],"Effectiveness":[34],"the":[36,50,67,147,166,176,191],"real":[37],"world,":[38],"however,":[39],"is":[40],"contingent":[41],"on":[42,56,138,196,206,242,273],"treatment":[43],"persistence":[44],"adherence.":[46],"Aim:":[47],"To":[48],"estimate":[49],"proportion":[51],"who":[54,219,287],"were":[55,202,220,268],"therapy,":[57,197,243,274],"persistent":[58,221,244,275],"had":[60],"high":[61,180,200,247,278],"adherence":[62,201,225,248,279],"at":[63,210,222,280],"365":[64,128,151,192,211,223,281],"days":[65,129,152,164,212,282],"following":[66,130,153],"initiation":[68,131],"a":[70,83,159,183],"PCSK9mAb":[71,84,207,228,250,267],"versus":[72,208,251],"ezetimibe":[73,97,209,230,252],"real-world":[75],"practice.":[77],"Methods:":[78],"We":[79,120],"included":[80],"adults":[81],"initiating":[82,266],"(n=":[85],"16,588,":[86],"44%":[87],"\u2265":[88,100,162,188],"65":[89,101],"years,":[90,102],"56%":[91],"male,":[92,104],"78%":[93],"ASCVD)":[95,107],"or":[96],"(n=83,086,":[98],"35%":[99],"51%":[103],"46%":[105],"from":[108,171],"Medicare":[109],"MarketScan":[111],"commercial":[112],"health":[113],"insurance":[114],"databases":[115],"between":[116,165],"7/2015":[117],"12/2019.":[119],"assessed":[121],"3":[122],"outcomes":[123],"using":[124],"pharmacy":[125,173],"claims":[126],"within":[127],"(assessment":[132],"period):":[133],"1)":[134],"percentage":[135,140,241],"therapy:":[139],"medication":[144],"supply":[145,170,186],"last":[148,167],"60":[149,163],"initiation;":[154],"2)":[155],"persistence:":[156],"not":[157],"having":[158,182,246],"gap":[160],"day":[168,184],"one":[172],"claim":[174],"next":[177],"claim;":[178],"3)":[179],"adherence:":[181],"for":[187,240],"80%":[189],"days.":[193],"Results:":[194],"Percentage":[195],"persistence,":[198],"higher":[203],"among":[204],"(Table":[213],"1).":[214],"When,":[215],"restricted":[216],"participants":[218],"days,":[224],"both":[227],"was":[231],"high.":[232],"The":[233],"adjusted":[234],"multivariable-adjusted":[235],"risk":[236],"ratio":[237],"[95%":[238],"CI]":[239],"was:":[253],"1.20":[254],"[1.18,":[255],"1.21],":[256],"1.22":[257],"[1.20,":[258],"1.24],":[259],"1.16":[261],"[1.14,":[262],"1.18].":[263],"Conclusions:":[264],"Patients":[265],"more":[269],"likely":[270],"be":[272],"compared":[283],"their":[285],"counterparts":[286],"initiated":[288],"ezetimibe.":[289],"Funding:":[290],"Amgen":[291],"Inc.":[292]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2023-12-20T00:00:00"}